Recent Finacing
Recent Raise
Sigilon develops Afibromer-based encapsulated cell therapies—engineered human cells shielded in biomaterial implants—to produce therapeutic proteins while preventing immune rejection and fibrosis for hemophilia, diabetes, lysosomal, endocrine, and immune diseases.
